Skip to main content
TipRanks
Go Ultimate75% OFF
Poplar Therapeutics logo

Poplar Therapeutics: Valuation, Funding & Investors

Boston, MA, UShttps://www.poplartx.com/Therapeutics

A clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a triple-action mechanism designed to block IgE binding, rapidly reduce circulating IgE, and inhibit its production to address multiple atopic diseases.

Leadership & Board

Current Number of Employees
7
Current LinkedIn Followers
1,400

Latest Estimated Valuation

Total Amount Raised
$50M
Total Funding Rounds
1
Latest Funding Amount
$50M
Latest Funding Round
Series A

Employee Trend

Poplar Therapeutics had 7 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.

7Latest Employee Count
0(0.00%)Week-Over-Week Change
05101520Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026Oct 26, 2026Nov 09, 2026

Social Trend

Poplar Therapeutics had 1,400 followers as of November 16, 2026. The number of followers increased by 5 (0.36%) week-over-week.

1,400Latest Followers Count
5(0.36%)Week-Over-Week Change
05001,0001,5002,000Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026Oct 26, 2026Nov 09, 2026

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Jan 07, 2026Series A$50.00M―

Investors

Investor NameFunding Round
SR OneSeries A
PlatanusSeries A
Vida VenturesSeries A

Similar Companies

A snapshot of private companies similar to Poplar Therapeutics, helping you discover and navigate related company profiles.

Related News and Analysis